ARTHRIX
HIKMA
Identification
- Active ingredient (INN)
- ETORICOXIB
- Internal code
- 04 B 080
- Country of Origin
- Algeria
- Pharmaceutical form
- Film-coated Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/30
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
mg film-coated tablets are indicated in adults and adolescents 16 years of age and older for symptomatic treatment of osteoarthritis.
The decision to prescribe a selective
COX-2 inhibitor should be based on the assessment of all patient-specific risks.
Associated Conditions
In the case of a patient with absorptive acid, the risk of absorptive disease is not significantly different from that of absorptive acid.
Mechanism of Action
The second-stage drug-related treatment of the drug was a low-level drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related drug-related.
Adverse Effects
In clinical trials, the safety of l-etoricoxib was evaluated in 9,295 subjects, of whom were osteoarthritis, rheumatoid arthritis (RP), low chronic lombalgia or ankylosing spondylitis (approximately 600 osteoarthritis or PR patients were treated for one year or more).
In clinical studies, the profile of adverse events in this study was similar in patients with osteoarthritis or PR treated with etoricoxib for at least one year.
In a clinical study involving gout attack, patients were treated with l-etoricoxib 120 mg once daily for 8 days.
The profile of adverse events in this study was generally similar to that of patients with osteoarthrosis or PR treated with osteoarthrosis or PR for at least one year.
In a program evaluating cardiovascular safety from the results of three controlled studies involving active comparators, 17 412 patients with osteoarthrosis, recombinant ogm for a study involving osteoarthrosis or a study involving a drug for a drug for a drug for a period of a period of a.